Akouos Inc., of Boston, which launched in 2016 and develops gene therapies for inner ear disorders, has adjusted the terms for its IPO and now plans to raise $213 million by offering 12.5 million shares priced at $17. The company is developing lead candidate AK-OTOF, a gene therapy focused on restoring hearing in individuals with sensorineural hearing loss due to mutations in the otoferlin gene. AK-OTOF uses an adeno-associated viral vector to deliver a healthy copy of the OTOF gene to cochlear hair cells, with the goal of restoring long-term physiologic hearing following a single administration to the inner ear. The company plans to list its shares on Nasdaq under the ticker AKUS.
Atara Biotherapeutics Inc., of South San Francisco, said the underwriters of its recently closed underwritten offering have exercised in full their option to purchase an additional 2.32 million shares. That brings the net proceeds to approximately $189.4 million. Shares of Atara (NASDAQ:ATRA) closed June 25 at $14.02, up $1.10.
Basilea Pharmaceutica Ltd., of Basel, Switzerland, said it completed an offering of CHF125 million (US$ 131.8 million) senior unsecured convertible bonds due 2027, fully exercising an increase option of CHF25 million. The proceeds from the offering will be used to finance a planned tender offer for the outstanding convertible bonds and for general corporate purposes. The bonds will have a maturity of seven years and will be convertible into shares sourced from existing conditional capital and existing treasury shares. They will carry a coupon of 3.25% per annum, payable semi-annually in arrears. Separately, the company reported a partial repurchase offer of at least CHF90 million and up to CHF110 million in principal amount of its outstanding convertible bonds due 2022.
Castle Biosciences Inc., of Friendswood, Texas, said it priced its underwritten public offering of 2 million shares at $37 each with gross proceeds expected to be $74 million. The underwriters have been granted a 30-day option to purchase up to an additional 300,000 shares.
Evelo Biosciences Inc., of Cambridge, Mass., said it priced an underwritten public offering of 12 million shares at $3.75 each. The underwriters have been granted a 30-day option, solely to cover overallotments, to purchase up to an additional 1.8 million shares. The gross proceeds are expected to be approximately $45 million, excluding any exercise of the underwriters' option to purchase additional shares. The company intends to use the net proceeds to advance EDP-1815 into two phase II trials and a phase II/III trial for the treatment of inflammatory diseases and hyperinflammation caused by viral infections, including SARS-CoV-2. The funds will also advance EDP-1815 in a phase Ib trial in atopic dermatitis with an enteric capsule formulation.
Fusion Pharmaceuticals Inc., of Hamilton, Ontario, has increased the terms for its IPO and now plans to raise up to $188 million by offering 12.5 million shares at a price range of $14 to $16. Its Fast-Clear linker technology platform attaches alpha particle-emitting isotopes to targeting molecules to create radiopharmaceuticals for the treatment of cancer. The lead program, FPI-1434, is currently in a phase I study for solid tumors expressing insulin-like growth factor 1 receptor. It plans to list its shares on Nasdaq under the symbol FUSN.
Hutchison China Meditech Ltd. (Chi-Med), of London, said it is selling $100 million of shares at a price equivalent to $25 per American depositary share (ADS) via a private placement to growth equity firm General Atlantic. The transaction could increase to $200 million, through a warrant granted with a term of 18 months for a further $100 million in Chi-Med shares exercisable at a price per share equivalent to $30 per ADS. The proceeds will fund ongoing research and clinical development and support the further growth of its commercialization capabilities, both in China and globally.
Iteos Therapeutics Inc., of Cambridge, Mass., plans to raise up to $100 million in an IPO. Its lead product candidates are EOS-850, a small-molecule adenosine A2A receptor antagonist, and EOS-448, a fully human antibody targeted against the immune checkpoint TIGIT. In April, it raised $125 million from the second tranche of its series B, bringing the total for the round to $175 million and fueling clinical development of a pipeline of drugs targeting PD-1 resistance. The company plans to list its shares on Nasdaq under the symbol ITOS.
Magenta Therapeutics Inc., of Cambridge, Mass., said it priced an underwritten public offering of 7.5 million shares at $8 each. The underwriters have been granted a 30-day option to purchase up to an additional 1.125 million shares. The gross proceeds are expected to be $60 million, excluding any exercise of the underwriters’ option to purchase additional shares. Shares of Magenta (NASDAQ:MGTA) closed June 25 at $8.31, down $1.36.
Nantkwest Inc., of El Segundo, Calif., said it expects to raise gross proceeds of $80.1 million from a public offering of 3.7 million shares (NASDAQ:NK) priced at $9.50 each and an additional 3.7 million shares sold to its chairman, CEO and principal stockholder, Patrick Soon-Shiong. In addition, it granted underwriters of the offering, Piper Sandler & Co. and Lifesci Capital, up to 30 days to purchase an additional 1.1 million shares. Nantkwest said it would use net proceeds of the offering for clinical development, manufacturing, upgrades to its facilities and equipment, and for working capital, capital expenditures and other general corporate purposes.
Outlook Therapeutics Inc., of Monmouth Junction, N.J., closed its registered direct offering of 8.4 million shares with gross proceeds of about $10.2 million. H.C. Wainwright & Co. acted as the exclusive placement agent. Outlook said it plans to use the net proceeds for working capital and general corporate purposes, including in support of ONS-5010, an ophthalmic formulation of bevacizumab for use in retinal indications.
Relay Therapeutics Inc., of Cambridge, Mass., filed to raise up to $200 million in an IPO on Nasdaq, where it has applied to list shares under the symbol RLAY. Proceeds from the offering would be used to fund trials for RLY-1971, a SHP2 inhibitor the company is testing for the treatment of patients with advanced solid tumors, and studies of the FGFR2 inhibitor RLY-4008. The money would also support efforts at the company to identify a lead development candidate and advance RLY-PI3K1047. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Co. LLC and Guggenheim Securities LLC are acting as joint book-running managers.
Translate Bio Inc., of Lexington, Mass., announced that $125 million of its common stock (NASDAQ:TBIO) will be sold in an underwritten public offering. Goldman Sachs & Co. LLC, SVB Leerink and Evercore ISI are acting as joint book-running managers, while H.C. Wainwright & Co. and Roth Capital Partners are serving as co-lead managers. Shire Human Genetic Therapies, Inc., a subsidiary of Osaka, Japan-based Takeda Pharmaceutical Co. Ltd., is offering 6.8 million shares of Translate Bio’s common stock in the offering.
Xeris Pharmaceuticals Inc., of Chicago, announced a public offering of $20 million of its common shares (NASDAQ:XERS) and $60 million of convertible senior notes to fund sales and marketing costs for its first commercial product, Gvoke, a ready-to-use glucagon injection. Jefferies and SVB Leerink are acting as joint book-running managers for the offerings. Xeris expects to grant them a 30-day option to purchase up to $3 million of additional shares and a 30-day option to purchase up to $9 million worth of convertible notes.